<code id='73CA3064AA'></code><style id='73CA3064AA'></style>
      • <acronym id='73CA3064AA'></acronym>
      <center id='73CA3064AA'><center id='73CA3064AA'><tfoot id='73CA3064AA'></tfoot></center><abbr id='73CA3064AA'><dir id='73CA3064AA'><tfoot id='73CA3064AA'></tfoot><noframes id='73CA3064AA'>
      • <optgroup id='73CA3064AA'><strike id='73CA3064AA'><sup id='73CA3064AA'></sup></strike><code id='73CA3064AA'></code></optgroup>
        5. <b id='73CA3064AA'><label id='73CA3064AA'><select id='73CA3064AA'><dt id='73CA3064AA'><span id='73CA3064AA'></span></dt></select></label></b><u id='73CA3064AA'></u>
          <i id='73CA3064AA'><strike id='73CA3064AA'><tt id='73CA3064AA'><pre id='73CA3064AA'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / fashion      
           
     
           
      
          fashion 
           
      
           
      
           
       2025-08-04 05:23:01 
   
      
           
      
           
                        
          fashion  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：9
                                  
                                    
          
                                   
          Johnson & Johnson sign
          MARK RALSTON/AFP via Getty Images
          WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.
          J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.
          advertisement
          The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          House passes resolution saying Israel isn't a 'racist or apartheid state'
                                
                            
          Next article：  
                                      
                                          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles